Krause und Pachernegg
Verlag für Medizin und Wirtschaft
Artikel   Bilder   Volltext

Mobile Version
A-  |   A  |   A+
Werbung
 
Dia-Präsentation von Merck Gesellschaft mbH.
Micardis(R) - Micardis Plus(R) - Klinische Wirksamkeit (39 Abbildungen)
Übersicht


Zum ersten Bild Abb. 29: Telmisartan - HCTZ Abb. 30: Telmisartan - HCTZ Abb. 31: Telmisartan - HCTZ Aktuelles Bild - Abb. 32: Telmisartan - Losartan - HCTZ Abb. 33: Telmisartan - Losartan - HCTZ Abb. 34: Telmisartan - Valsartan - HCTZ Abb. 35: Telmisartan - HCTZ Zum letzten Bild
Abbildung 32: Telmisartan - Losartan - HCTZ
Telmisartan 40 mg in combination with HCTZ was superior to losartan 50 mg in combination with HCTZ in two 6-week, prospective, randomized, open-label, blinded endpoint (PROBE) studies.1,2 The studies compared telmisartan 40 mg + HCTZ 12.5 mg, telmisartan 80 mg + HCTZ 12.5 mg and losartan 50 mg + HCTZ 12.5 mg. Both telmisartan groups were also significantly superior to losartan in the mean change from baseline in SBP in the last 6 h of the dosing interval. 1. Neutel JM, et al. Telmisartan 40 or 80 mg/HCT 12.5 mg fixed-dose combinations provide superior BP reductions compared with losartan 50 mg/HCT 12.5 mg fixed-dose combination: an ABPM comparison. Am J Hypertens 2004; 17(5 pt 2): 118A. 2. Lacourcière Y, et al. Efficacy and tolerability of fixed-dose combinations of telmisartan plus HCTZ compared with losartan plus HCTZ in patients with essential hypertension. Int J Clin Pract 2003; 57: 273–279.
 
Telmisartan - Losartan - HCTZ
Vorheriges Bild Nächstes Bild   


Abbildung 32: Telmisartan - Losartan - HCTZ
Telmisartan 40 mg in combination with HCTZ was superior to losartan 50 mg in combination with HCTZ in two 6-week, prospective, randomized, open-label, blinded endpoint (PROBE) studies.1,2 The studies compared telmisartan 40 mg + HCTZ 12.5 mg, telmisartan 80 mg + HCTZ 12.5 mg and losartan 50 mg + HCTZ 12.5 mg. Both telmisartan groups were also significantly superior to losartan in the mean change from baseline in SBP in the last 6 h of the dosing interval. 1. Neutel JM, et al. Telmisartan 40 or 80 mg/HCT 12.5 mg fixed-dose combinations provide superior BP reductions compared with losartan 50 mg/HCT 12.5 mg fixed-dose combination: an ABPM comparison. Am J Hypertens 2004; 17(5 pt 2): 118A. 2. Lacourcière Y, et al. Efficacy and tolerability of fixed-dose combinations of telmisartan plus HCTZ compared with losartan plus HCTZ in patients with essential hypertension. Int J Clin Pract 2003; 57: 273–279.
 
copyright © 2003–2017 Krause & Pachernegg GmbH | Sitemap | Impressum
 
Werbung